M&A Deal Summary |
|
|---|---|
| Date | 2012-09-24 |
| Target | CNS Therapeutics |
| Sector | Life Science |
| Buyer(s) | Mallinckrodt |
| Deal Type | Add-on Acquisition |
| Deal Value | 100M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1867 |
| Sector | Life Science |
| Employees | 2,673 |
| Revenue | 2.2B USD (2021) |
Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 13 |
| Sector: Life Science M&A | 1 of 9 |
| Type: Add-on Acquisition M&A Deals | 2 of 10 |
| State: Minnesota M&A | 1 of 1 |
| Country: United States M&A | 2 of 11 |
| Year: 2012 M&A | 1 of 1 |
| Size (of disclosed) | 7 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 1999-12-17 |
HemoCue AB
Angelholm, Sweden For more than 10 years, HemoCue had been a recognized global leader in professional diagnostics point-of-care testing. The product strategies behind HemoCue's success where based on a clear focus on important diagnostic tests of the highest quality, which was fast and easy to perform by anyone. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-02-11 |
Cadence Pharmaceuticals
San Diego, California, United States Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. |
Buy | $1.3B |
